DrugDashboards

Daptomycin

Daptomycin · DAPTOMYCIN 500 mg/10mL · Injection, Powder, Lyophilized, For Solution · Patheon Italia S.p.A.

NDC 68225-0082-01 · 96 BOX in 1 CONTAINER / 108 VIAL, SINGLE-USE in 1 BOX / 10 mL in 1 VIAL, SINGLE-USE · DRUG FOR FURTHER PROCESSING · View full market →

Bulk ingredient — not a finished product

This NDC is a raw material (drug for further processing) sold to drug manufacturers or compounders, not a product pharmacies dispense. Retail pricing, TE codes, fragility scores, and shortage reports don't apply to bulk listings — those attach to finished products made from this ingredient.

Medicare Part D

All Part D pricing →

Matched to CMS's representative package for this drug (NDC 60505-6229-04) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.

ⓘ How this was built
Data sources
  • CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method

Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

Plans pay at point of saleⓘ
$52.81per unit
middle half $33.85–$92.73 · 5,496 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $52.81
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
100%of plans cover it
tier 5 · prior auth 0% · step therapy 0% · qty limit 0%

*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.5%chance of a new FDA shortage posting for daptomycin (injectable) in the next 90 days

sterile injectable · OAI inspection at a producing facility (24 months) · sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is 3× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

  • Part D specialty tier
  • Costs ≥ $950/fill · avg $790.29 per prescription
  • Biologic (BLA)
  • Injectable / infused
  • Orphan-drug exclusivity
  • REMS program

Regulatory

Application
—
TE code
—
Approval date
—
Patents / exclusivity
—

Shortage history

  • Planned discontinuation — Daptomycin, Injection, 500 mg/10 mL (NDC 0143-9378-01)Jun 30, 2026

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Daptomycin (Injection, Powder, Lyophilized, For Solution)

LabelerStrengthFirst seenLast seen
Fresenius Kabi USA, LLCDAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 3, 2026
Hikma Pharmaceuticals USA Inc.DAPTOMYCIN 350 mg/7mLJul 15, 2026Sep 3, 2026
Meitheal Pharmaceuticals Inc.DAPTOMYCIN 350 mg/7mLJul 15, 2026Sep 3, 2026
Meitheal Pharmaceuticals Inc.DAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 3, 2026
Mylan Institutional LLCDAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 3, 2026
Sagent PharmaceuticalsDAPTOMYCIN 350 mg/7mLJul 15, 2026Sep 3, 2026
Xellia Pharmaceuticals USA LLCDAPTOMYCIN 350 mg/7mLJul 15, 2026Sep 3, 2026
Xellia Pharmaceuticals USA LLCDAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 3, 2026
Accord Healthcare Inc.DAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 2, 2026
Accord Healthcare, Inc.DAPTOMYCIN 350 mg/7mLJul 15, 2026Sep 2, 2026
Apotex Corp.DAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 2, 2026
BE Pharmaceuticals Inc.DAPTOMYCIN 350 mg/7mLJul 15, 2026Sep 2, 2026
BE Pharmaceuticals Inc.DAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 2, 2026
Biocon Pharma Inc.DAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 2, 2026
BluePoint LaboratoriesDAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.DAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 2, 2026
Camber Pharmaceuticals, Inc.DAPTOMYCIN 350 mg/7mLJul 15, 2026Sep 2, 2026
Civica, Inc.DAPTOMYCIN 350 mg/7mLJul 15, 2026Sep 2, 2026
Dr. Reddy's Laboratories Inc.,DAPTOMYCIN 350 mg/7mLJul 15, 2026Sep 2, 2026
Dr.Reddy's Laboratories Inc.,DAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 2, 2026
Eugia US LLCDAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 2, 2026
Hospira, Inc.DAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 2, 2026
Hospira, Inc.DAPTOMYCIN 350 mg/7mLJul 15, 2026Sep 2, 2026
MAIA Pharmaceuticals, Inc.DAPTOMYCIN 500 mg/1Jul 15, 2026Sep 2, 2026
NorthStar RxLLCDAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 2, 2026
NorthStar RxLLCDAPTOMYCIN 350 mg/7mLJul 15, 2026Sep 2, 2026
Par Health USA, LLCDAPTOMYCIN 500 mg/1Jul 15, 2026Sep 2, 2026
Patheon Italia S.p.ADAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 2, 2026
Patheon Italia S.p.A.DAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 2, 2026
Qilu Pharmaceutical Co., Ltd.DAPTOMYCIN 500 mg/10mLJul 15, 2026Sep 2, 2026
Sagent PharmaceuticalsDAPTOMYCIN 50 mg/mLJul 15, 2026Sep 2, 2026
Hikma Pharmaceuticals USA Inc.DAPTOMYCIN 500 mg/10mLJul 15, 2026Aug 31, 2026
Aspiro Pharma LimitedDAPTOMYCIN 500 mg/10mLAug 28, 2026Aug 28, 2026
Civica, Inc.DAPTOMYCIN 500 mg/10mLJul 15, 2026Aug 28, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Daptomycin — NDC 68225-0082-01," retrieved September 3, 2026, https://drugdashboards.com/drug/68225008201.

Free to cite with attribution — see how the data is put together.